Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01264497
Recruitment Status : Completed
First Posted : December 21, 2010
Last Update Posted : December 21, 2010
Information provided by:

December 17, 2010
December 21, 2010
December 21, 2010
February 2002
November 2002   (Final data collection date for primary outcome measure)
Change from baseline in relative insulin response
Same as current
No Changes Posted
  • Change from baseline in glycosylated hemoglobin (HbA1c)
  • Change in mean daily serum glucose concentrations
    Home blood glucose will be obtained four times per day (before breakfast, lunch, and dinner, and at bedtime) using a standard blood glucose meter
  • Changes in the number of dose adjustments per week for insulin and/or oral hypoglycemic agents
  • Number of subjects with a change in the control of diabetes
Same as current
Not Provided
Not Provided
Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes
A Double-blind, Randomized, Parallel, Placebo-controlled 12-week Evaluation of the Safety of Two Doses of TH9507 in Subjects With Stable, Type 2 Diabetes Mellitus
The purpose of this study was to determine whether TH9507, a stabilized analogue of growth hormone-releasing factor (GRF), would have an effect on insulin sensitivity or control of diabetes in patients with type 2 diabetes.
Not Provided
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Type 2 Diabetes
Drug: TH9507
1 and 2 mg, sc daily for 12 weeks
Not Provided
Clemmons DR, Miller S, Mamputu JC. Safety and metabolic effects of tesamorelin, a growth hormone-releasing factor analogue, in patients with type 2 diabetes: A randomized, placebo-controlled trial. PLoS One. 2017 Jun 15;12(6):e0179538. doi: 10.1371/journal.pone.0179538. eCollection 2017.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
November 2002
November 2002   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male or postmenopausal or surgically sterilized female subjects, 50 years of age or older;
  • Documented diagnosis of type 2 diabetes as defined by the American Diabetes Association;
  • Diagnosis of type 2 diabetes for at least 3 months before screening;
  • Subjects on stable diabetes treatment regimens (receiving oral hypoglycemics with or without insulin) for at least 2 months before screening;
  • Screening and pre-randomization glycosylated hemoglobin (HbA1c) <10.0%, according to central laboratory;
  • Body mass index (BMI) between 25 and 38 kg/m2
  • Subjects willing to perform specified home blood glucose monitoring and comply with all study protocol requirements;
  • Signed informed consent.

Exclusion Criteria:

  • Serum creatinine >2 mg/dL;
  • Fasting triglycerides >1000 mg/dL;
  • Albuminuria >200 mg/24 hours;
  • Positive mammography (if female) or prostate-specific antigen (PSA) or prostate examination for cancer (if male);
  • Use of oral or parenteral glucocorticoids in the 30 days before screening;
  • Use of any experimental or marketed growth hormone, growth hormone secretagogues, insulin-like growth factor-1 (IGF-1), or insulin-like growth factor binding protein-3 (IGFBP-3) during the previous 6 months;
  • Subjects with two or more severe hypoglycemia episodes within the past 6 months, or any hospitalization or emergency room visit due to poor glycemic control within the past 6 months. Similarly, during the lead-in period, any subject with more than one severe hypoglycemic episode or any hospitalization or emergency room visit due to poor glycemic control will be excluded from randomization;
  • History of or presence of active concomitant conditions or diseases (e.g., myocardial infarction, poorly controlled hypertension, thyroid disease, rheumatoid arthritis, seizure disorder, diabetic neuropathy, diabetic retinopathy [except subjects with only microaneurysms on fundus examination]) that would interfere with the protocol conduct and endpoint measurements;
  • Subjects with a major surgical operation during the 30 days before screening;
  • Subjects with known hypopituitarism, history of pituitary tumor/surgery, head irradiation, or severe head trauma;
  • Current cancer or history of cancer, except non-melanomatous skin cancer;
  • Subjects with active infection at any body site or a history of severe infection (requiring oral or parenteral treatment) during the 30 days before screening;
  • Subjects with clinically significant abnormalities on screening laboratory evaluation (unless discussed with and approved by the medical monitor);
  • Subjects with allergy to synthetic growth hormone products or their excipients;
  • Subjects who had previously received growth hormones in any clinical trial;
  • Participation in a trial of an experimental drug or device within 90 days before screening.
Sexes Eligible for Study: All
50 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Not Provided
Bruno Lussier/Medical Director, Theratechnologies
Not Provided
Not Provided
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP